Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial

Bharathi S. Gadad, Manish K. Jha, Bruce D. Grannemann, Taryn L. Mayes, Madhukar H. Trivedi

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Animal and human studies suggest an association between depression and aberrant immune response. Further, common inflammatory markers may change during the course of antidepressant treatment in patients. The objective of this study was to evaluate changes in inflammatory markers and clinical outcomes from subjects enrolled in the Combining Medications to Enhance Depression Outcome (CO-MED) trial. At baseline and week 12 (treatment completion), plasma samples of 102 participants were analyzed via a multiplex assay comprised of inflammatory markers using a 27-plex standard assay panel plus a 4-plex human acute phase xMAP technology based platform. We carried out analyses in two steps. First, t-tests were used to identify inflammatory marker levels that changed between baseline and week 12. For markers that were altered, logistic regression models were then conducted to look for associated changes in remission at week 12. Among the 31 inflammatory markers analyzed, several cytokines (IL-5, IFN-γ, IL-13), two chemokines (Eotaxin-1/CCL11, RANTES) and an acute-phase reactant (serum amyloid P component) showed change from baseline to week 12. However, only two indicated differential remission responses. Interestingly, increased levels of Eotaxin-1/CCL11 correlated with remission at week 12, whereas decreased levels of IFN-γ correlated with non-remission at week 12. Results suggest that these inflammatory proteins may serve as predictors of treatment response.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalJournal of Psychiatric Research
StatePublished - Nov 2017


  • Antidepressant
  • Cytokine
  • Eotaxin-1/CCL11
  • IFN-γ
  • Multiplex
  • Predictor

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial'. Together they form a unique fingerprint.

Cite this